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1. Introduction 
Myocarditis is an inflammatory disease of the cardiac muscle which might be related to viral 
(mainly parvovirus B19 and many others), protozoan (Borrellia burgdoferi, Trypanosoma cruzi, 
Toxoplasma gondi),  bacterial (Brucella, Corynebacterium diphtheriae, Gonococcus, Haemophilus 
influenzae, Actinomyces, Tropheryma whipplei, Vibrio cholerae, Borrelia burgdorferi, Leptospira, 
Rickettsia), fungal (Aspergillus) and other non viral pathogens (Rezkalla SH et al., 2010, 
Blauwet LA et al., 2010, Cihakova D et al., 2010) infections; It has been reported, however, 
that this kind of inflammation might be caused by an hypersensitivity response to drugs 
(Kühl U et al., 2009). The final effect in each case is represented by myocardial infiltration of 
immunocompetent cells following any kind of cardiac injury.  
Myocarditis presents with many symptoms, from chest pain that spontaneously resolves 
without treatment to cardiogenic shock and sudden death (Kühl U et al., 2010, Taylor CL et 
al 2010). The major long-term consequence is dilated cardiomyopathy with chronic heart 
failure(Lv H et al. 2011, Stensaeth KH et al 2011).  
Nowadays, diagnostic tools available for this disease are mainly related to general 
investigations (such as electrocardiography) and analysis of the most abundant serum 
proteins, whose alteration is related to cardiac pathology, even if it’s not specifically 
connected to myocarditis itself.  Here we propose preliminary speculations on the serum 
proteins profiling (both in the expression level and in the characterization of post 
translational modifications) and on free peptides identification in myocardytis affected 
patients (compared to healthy individual), that could be helpful in finding specific markers 
for this pathology.   
As many other inflammatory events this disease involves in fact different kinds of biological 
macromolecules, here we focus in particular on proteins. More than 50% of total protein 
content in a cell is post translationally modified. The pattern of Post Translational 
Modifications (PTMs) on proteins constitute a molecular code that dictates protein 
conformation, cellular location, macromolecular interactions and activities, depending on 
cell type, tissue and environmental conditions (Diernfellner AC et al., 2011, Savidge TC, 
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2011, Hao P et al.,2011). It is very well known that biological function of many proteins is 
strictly related to the presence of the appropriate set of PTMs. Most importantly, PTMs 
deregulation might be involved in the development of diseases , in fact, as a consequence of 
many pathologies, PTMs set might be altered (Dell A  et al., 2001, Kim YJ. Et al 1997, Dube 
DH. Et al., 2005, Granovsky M. Et al 2000). 
Proteomics investigations offer all useful tools to deeply investigate this kind of alterations. 
Two dimensional electrophoresis coupled with software mediated image analysis, affinity 
chromatographies and especially Mass Spectrometry (MS) present high levels of sensitivity, 
accuracy and reproducibility and these are all fundamental requirements that this kind of 
study needs.   
As previously described by our group (Carpentieri A, Giangrande C, et al., 2010), serum 
glycoproteome characterization might be crucial in clinical investigation.  In fact we showed 
that the N-glycan profiling of serum glycoproteins extracted from myocarditis affected 
donors compared to the ones of healthy people shows many peculiarities. We demonstrated 
that many of the extracted oligosaccharides are in fact incomplete or truncated structures 
whilst others show a high level of fucosylation, all these results fully matched previously 
published data about the glycosylation in proteins during chronic inflammation events (Dell 
A  et al., 2001, Kim YJ. Et al 1997, Dube DH. Et al., 2005, Granovsky M. Et al 2000, 
Carpentieri A, Giangrande C, et al., 2010).  
Thanks to the high sensitivity of the most modern analytical techniques, several research 
groups focus the research at level of peptides rather than at protein level (Taylor-
Papadimitriou J.  et al., 1994 Amado F et al., 2010, Menschaert G et al. 2010). In fact, these 
endogenous peptides are referred to as the peptidome. Initially, peptidomic analyses were 
conducted as a method to study neuropeptides and peptide hormones; these are signaling 
molecules that function in a variety of physiological processes (Ludwig M. 2011, Colgrave 
ML et al., 2011). Recent studies have found large numbers of cellular peptides with half-lives 
of several seconds, raising the possibility that they may be involved in biological functions 
(Gorman PM  et al 2003). 
Here we propose preliminary data to show molecular basis of myocarditis using a 
proteomic approach. The analyses were focused on the serum proteins profiling, namely the 
study of the expression level and the characterization of glycoproteins involved in the 
pathology.  A classical two-dimensional gel electrophoresis procedure to obtain protein 
maps and a “gel-free” comparison of the glycoproteomes in healthy and myocarditis human 
sera by using advanced mass spectrometry were reported. Free peptides identification in 
myocardytis affected patients (compared to healthy individual), was achieved in order to 
provide possible specific markers for this pathology.   
2. Materials and methods 
2.1 Materials 
Human serum samples from 8 healthy donors (all Caucasian 4 males and 4 females aged 
between 60 and 80 years, all other clinical informations were covered by laws on privacy) 
and from 5 myocarditis affected patients (all Caucasian 3 males and 2 females aged between 
60 and 85 years, all other clinical informations were covered by laws on privacy), 
respectively, have been obtained from the “Servizio Analisi” Policlinico, Napoli.  Aliquots of 
serum samples from different donors were pooled in order to obtain an average overview of 
glycoforms distribution. 
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Guanidine, dithiothreitol (DTT), trypsin, α-cyano-4-hydroxycinnamic acid were purchased 
from Sigma. Iodoacetamide (IAM), tris(hydroxymethyl)aminomethane, calcium chloride 
and ammonium bicarbonate (AMBIC) were purchased from Fluka as well as the MALDI 
matrix 2,5-, α-cyano-4-hydroxycinnamic. Methanol, trifluoroacetic acid (TFA) and 
acetonitrile (ACN) are HPLC grade type from Carlo Erba, whereas the other solvents are 
from Baker. Gel filtration columns PD-10 are from Pharmacia, the HPLC ones from 
Phenomenex, whereas the pre-packed columns Sep-pak C-18 are from Waters. 
Comassie Brilliant Blue was from Bio-Rad. PNGase F were purchased from Boheringer. Ion 
exchange resins Dowex H+ (50W-X8 50-100 mesh) was provided by BDH. Concanavalin A 
sepharose resin was purchased from Amersham Biosciences.  
2.2 Protein concentration determination 
Sera protein concentration was determined by Bradford assay method, using bovine serum 
albumin (BSA) as standard. Known amounts of BSA were diluted in 800 μL of H2O and 
then mixed to 200 μL of Comassie Brilliant Blue. 5 different BSA concentrations were 
determined by measuring absorbance at 595 nm and used to obtain a linear calibration 
curve. Three different sera dilutions were measured at 595 nm. Absorbance data were 
interpoled on the calibration curve, allowing the determination of protein concentration in 
the different samples.  
2.3 Serum depletion 
The depletion of the most abundant proteins from each serum sample was performed using 
Multiple Affinity Removal Spin Cartridges from Agilent. The procedure was performed at 
room temperature according to manufacturer’s instructions and then immediately frozen to 
-20°C. 
2.4 Free peptides analysis 
300 μL acetonitrile was added to 100 μL of serum, incubated at room temperature for 30 
minutes and then centrifuged at 13000 rpm. Supernatants were collected and concentrated 
by vacuum centrifugation (SAVANT) and resuspended in 20 μL formic acid 0.1%. Samples 
were desalted by C18  Zip Tip (Millipore) and diluted 100 times prior mass spectrometry 
analyses.  
LC/MS-MS HPLC-Chip/Q-TOF 6520 
Peptides were analyzed by a HPLC-Chip/Q-TOF 6520 (Agilent Technologies). The capillary 
column works at a flow of 4 μL/min, concentrating and washing the sample in a 40 nL 
enrichment column. The sample was then fractionated on a C18 reverse-phase capillary 
column (75 μm~43 mm in the Agilent Technologies chip) at flow rate of 400 nl/min, with a 
linear gradient of eluent B (0.2% formic acid in 95% acetonitrile) in A (0.2% formic acid in 
2% acetonitrile) from 7% to 60% in 50 min. 
Data were acquired through MassHunter software (Agilent Technologies). Proteins 
identification was achieved by using Mascot software (Matrix science), with a tolerance of 10 
ppm on peptide mass, 0.6 Da on MS/MS, and choosing methionine oxidation and glutamine 
conversion in pyro-glutamic acid as variable modifications. 
MALDI-TOF/TOF 
Peptides were also analyzed by MALDI-TOF/TOF using a 4800 Plus MALDI-TOF/TOF 
(Applied Biosystems). Samples were mixed on MALDI plate to the matrix consisting of a 
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solution of 10 mg/mL α-cyano-4-hydroxycinnamic, whose preparation consisted in the 
resuspension of α-cyano-4-hydroxycinnamic in water and acetonitrile 10:1 (v/v). The 
instrument was calibrated using a mixture of standard peptides (Applied Biosystems). 
Spectra were register even in reflector positive. MS/MS spectra were performed with CID 
using air as collision gas. Spectra were manually interpreted. 
2.5 2D-gel electrophoresis  
IEF (first dimension) was carried out on non-linear wide-range immobilized pH gradients 
(pH 4-7; 7 cm long IPG strips; GE Healthcare, Uppsala, Sweden) and achieved using the 
EttanTM IPGphorTM system (GE Healthcare, Uppsala, Sweden). Analytical-run IPG-strips 
were rehydrated with 125μg of total proteins in 125μl of rehydratation buffer (urea 8 M, 
CHAPS 2%, 0,5% (v/v) IPG Buffer, bromophenol blue 0,002%) for 12 h at 20°C. The strips 
were then focused according to the following electrical conditions at 20°C: 500 V for 30 min, 
from 1000 V for 30 min, 5000 V  until a total of 15000 Vt was reached. After focusing IPG 
strips were equilibrated for 15 min in 6 M urea, 30% (vol/vol) glycerol, 2% (wt/vol) SDS, 
0.05 M Tris-HCl, pH 6.8, 2% (wt/vol) DTT, and subsequently for 15 min in the same 
urea/SDS/Tris buffer solution but substituting the 2% (wt/vol) DTT with 2.5% (wt/vol) 
iodoacetamide. The second dimension was carried out on 12% polyacrylamide gels  at 25 
mA/gel constant current until the dye front reached the bottom of the gel. MS gel was 
stained with colloidal comassie. 
2.6 Image analysis 
Gels images were acquired with an Epson expression 1680 PRO scanner. Computer-aided 
2-D image analysis was carried out using the ImageMasterTM 2D Platinum software (GE 
Healthcare, Uppsala, Sweden).  Differentially expressed spots were selected for MS 
analysis. 
In order to find differentially expressed proteins, comassie stained gel image of serum 
proteins from healthy individual was matched with the one of myocarditis affected patient. 
The apparent isoelectric points and molecular masses of the proteins were calculated with 
ImageMaster 2D Platinum 6.0 using identified proteins with known parameters as 
references. 
Relative spot volumes (%V) (V=integration of OD over the spot area; %V = V single spot/V 
total spot) were used for quantitative analysis in order to decrease experimental errors. The 
normalized intensity of spots on three replicate 2-D gels was averaged and standard 
deviation was calculated for each condition. 
2.7 Protein identification by mass spectrometry 
In situ digestion 
Protein spots were excised from the gel and destained by repetitive washes with 0.1 M 
NH4HCO3 pH 7.5 and acetonitrile. Enzymatic digestion was carried out with trypsin (12.5 
ng/µl) in 10 mM ammonium bicarbonate buffer pH 7.8. Gel pieces were incubated at 4 °C 
for 2 h. Trypsin solution was then removed and a new aliquot of the same solution was 
added; samples were incubated for 18 h at 37 °C. A minimum reaction volume was used as 
to obtain the complete rehydratation of the gel. Peptides were then extracted by washing the 
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gel particles with 10mM ammonium bicarbonate and 1% formic acid in 50% acetonitrile at 
room temperature. 
Mass spectrometry and protein identification 
LC-MS/MS analyses were performed as previously described for free peptides. 
Mass spectrometric obtained data were used for protein identification using the software 
MASCOT that compare peptide masses obtained by MS and MS/MS data of each tryptic 
digestion with the theoretical peptide masses from all the proteins accessible in the 
databases (Peptide Mass Fingerprinting, PMF). Database searches were performed in NBCI 
databank (National Center for Biotechnology Information), restricting the analysis to the 
pertinent taxonomies. The parameters used for the identification were: tolerance of 10 ppm 
on peptide mass, 0.6 Da on MS/MS, and cysteine carbamidomethylation as fixed 
modification. Variable modifications were methionine oxidation, glutamine conversion in 
pyro-glutamic acid, and asparagine deamidation. 
2.8 Boronate affinity chromatography 
Glycoproteins were purified using PBA-bound agarose (Sigma-Aldrich, Munich, Germany). 
500 µl of sample previously diluted (1 : 1) with equilibration buffer (50 mM taurine/NaOH, 
pH 8.7, containing 3–10 mM MgCl 2 ) was incubated with 200 µl of pre-washed immobilized 
ligand resin for 1 h on ice and with gentle shaking. After transfer of the resin into 1,5 ml 
eppendhorf tubes, the non-binding fraction was collected by low speed centrifugation (10 s, 
500 × g). The resin was then thoroughly rinsed with equilibration buffer (six washes of 150 
µl each) and 1 N NaCl (three washes of 150 µl each). For final elution of the bound fraction, a 
total of six washes (150 µl each) with taurine buffer containing 50 mM sorbitol were used. 
Three successive fractions (150 µl each) were pooled before further analysis. 
2.9 Deglycosylation 
Glycopeptides were lyophilized, resuspended in 10 mM AMBIC and incubated with 
PNGase F (5 U), for 12-16 h at 37°C. Deglycosylation was carried out also on unbound 
peptides, in order to release the glycans not recognized by Boronate affinity 
chromatography. 
3. Results and discussion 
3.1 Free peptides analysis  
The analyses to investigate the “peptidomic” both in healthy and in pathological samples 
were accomplished by using a gel-free approach. The peptide component of the eluted 
fraction was analyzed by tandem mass spectrometry. The stringency of scoring parameters 
of the MASCOT algorithm minimized the number of false positive identifications. Most 
MS/MS spectra giving positive hits were derived from doubly and triply charged precursor 
ions that resulted predominantly in y-ion series. 
Triplicate LC-MS/MS analysis of supernatants after ACN precipitation of serum proteins, 
showed the occurrence of many free peptides in both analyzed sera. As reported in Table 1, 
the total number of detected and identified peptides was 41. Among these, 9 peptides were 
unique in the pathologic sample. It should be noted that some peptides were identified in 
both samples.   
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m/z RT Sequence Peptide Protein 
H/M 
ratio 
567.95 17.09 QAGAAGSRMNFRPGVLS (650-666) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
513.78 17.70 YYLQGAKIPKPEASFSPR (627-644) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
823.17 22.11 
MNFRPGVLSSRQLGLPGPPDVPDH
AAYHPF 
(658-687) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
1005.98 22.78 QLGLPGPPDVPDHAAYHPF (669-687) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
0.68±0.18 
757.71 19.96 SRQLGLPGPPDVPDHAAYHPF (667-687) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
0.27±0.09 
681.85 22.07 
PGVLSSRQLGLPGPPDVPDHAAYHP
F 
(662-687) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
0.18±0.03 
576.90 20.69 
PGVLSSRQLGLPGPPDVPDHAAYHP
FR 
(662-688) 
Q14624 Inter-alpha-
trypsin inhibitor heavy 
chain H4 
H:not 
detected 
379.71 0.55 LAEGGGVR (28-35) 
P02671 Fibrinogen alpha 
chain 
25±3.11 
453.24 3.65 FLAEGGGVR (27-35) 
P02671 Fibrinogen alpha 
chain 
2.48±0.57 
510.76 11.29 DFLAEGGGVR (26-35) 
P02671 Fibrinogen alpha 
chain 
1.33±0.76 
539.27 11.70 GDFLAEGGGVR (25-35) 
P02671 Fibrinogen alpha 
chain 
3.15±1.02 
597.77 15.59 SGEGDFLAEGGGV (22-34) 
P02671 Fibrinogen alpha 
chain 
0.85±0.23 
603.79 12.57 EGDFLAEGGGVR (24-35) 
P02671 Fibrinogen alpha 
chain 
2.42±0.63 
632.30 13.50 GEGDFLAEGGGVR (23-35) 
P02671 Fibrinogen alpha 
chain 
2.72±0.71 
655.28 16.03 DSGEGDFLAEGGGV (21-34) 
P02671 Fibrinogen alpha 
chain 
1.23±0.36 
675.81 13.67 SGEGDFLAEGGGVR (22-35) 
P02671 Fibrinogen alpha 
chain 
2.32±0.58 
690.80 16.13 ADSGEGDFLAEGGGV (20-34) 
P02671 Fibrinogen alpha 
chain 
3.25±0.82 
733.33 14.04 DSGEGDFLAEGGGVR (21-35) 
P02671 Fibrinogen alpha 
chain 
1.59±0.12 
768.85 14.08 ADSGEGDFLAEGGGVR (20-35) 
P02671 Fibrinogen alpha 
chain 
6.16±1.01 
851.71 13.58 SSSYSKQFTSSTSYNRGDSTFES (576-598) 
P02671 Fibrinogen alpha 
chain 
0.65±0.17 
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m/z RT Sequence Peptide Protein 
H/M 
ratio 
693.06 13.06 SSSYSKQFTSSTSYNRGDSTFESKS (576-600) 
P02671 Fibrinogen alpha 
chain 
M: not 
detected 
733.83 14.48 SSSYSKQFTSSTSYNRGDSTFESKSY (576-601) 
P02671 Fibrinogen alpha 
chain 
M: not 
detected 
619.75 17.89 QGVNDNEEGFF (31-41) 
P02675 Fibrinogen beta 
chain 
3.25±0.89 
663.26 16.54 QGVNDNEEGFFS (31-42) 
P02675 Fibrinogen beta 
chain 
1.97±0.41 
696.28 17.64 QGVNDNEEGFFSA (31-43) 
P02675 Fibrinogen beta 
chain 
2.31±0.53 
404.55 18.90 RIHWESASLL 
(1310-
1319) 
P01024 Complement C3 
H: not 
detected 
402.22 14.29 THRIHWESASLLR 
(1308-
1320) 
P01024 Complement C3 
H: not 
detected 
445.25 16.98 SKITHRIHWESASLL 
(1305-
1319) 
P01024 Complement C3 
H: not 
detected 
415.20 7.60 HWESASL 
(1312-
1318) 
P01024 Complement C3 
H: not 
detected 
471.74 16.21 HWESASLL 
(1312-
1319) 
P01024 Complement C3 
H: not 
detected 
851.07 22.22 TLEIPGNSDPNMIPDGDFNSYVR (957-979) 
P0C0L4 Complement 
C4-A 
H: not 
detected 
1054.53 25.86 DDPDAPLQPVTPLQLFEGR 
(1429-
1447) 
P0C0L4 Complement 
C4-A 
H: not 
detected 
489.96 20.26 RHPDYSVVLLLR (169-180) P02768 Serum Albumin 0.43±0.17 
417.91 16.67 KFQNALLVRY (426-435) P02768 Serum Albumin 
H: not 
detected 
547.31 16.25 KVPQVSTPTLVEVSR (438-452) P02768 Serum Albumin 
H: not 
detected 
868.11 21.57 
AVPPNNSNAAEDDLPTVELQGVVP
R 
(14-38) 
P00488 Coagulation 
factor XIII A 
2.40±0.84 
920.14 21.09 
RAVPPNNSNAAEDDLPTVELQGVV
PR 
(13-38) 
P00488 Coagulation 
factor XIII A 
23.60±3.61 
837.93 21.39 
TAFGGRRAVPPNNSNAAEDDLPTV
ELQGVVPR 
(7-38) 
P00488 Coagulation 
factor XIII A 
91.32±7.39 
781.37 17.84 TATSEYQTFFNPR (315-327) P00734 Prothrombin 
H: not 
detected 
868.46 25.47 TGIFTDQVLSVLKGEE (86-101) 
P02655Apolipoprotein 
C-II 
H: not 
detected 
572.95 12.91 DALSSVQESQVAQQAR (45-60) 
P02656Apolipoprotein 
C-III 
H: not 
detected 
803.76 21.14 AATVGSLAGQPLQERAQAWGERL (210-232) P02649Apolipoprotein E 0.02 
Table 1. List of free peptides identified by LC-MS/MS. Averaged area of chromatographic 
peaks from healthy(H) and myocarditis (M) ratio, indicates that some of them were 
differently represented. Peptide sequences were validated by MALDI-TOF/TOF analyses 
too. 
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As a whole, the LC-MS/MS proved to be a very sensitive and reproducible analysis which 
led to the identification of very weakly present peptides, these data were confirmed by 
another fragmentation technique, MALDI-TOF/TOF. As Fig. 1 shows, the fragmentation 
pattern of the peptide –ADSGEGDFLAEGGGVR- (from alpha fibrinogen protein) confirm 
what we found using LC-MS/MS analysis.  Some of these peptides are related to different 
proteolytic activities on proteins involved in acute phase or inflammatory events, such as 
myocarditis itself. Among identified peptides, the molecular species , namely, peptide 662-
668 from inter-alpha-trypsin inhibitor heavy chain H4 and peptide 1305-1319 from 
complement C3 correspond to free bioactive peptides, whose activity might be related again 
to inflammatory events (van den Broek I et al, 2010, ter Weeme M, et al, 2009).   Preliminary 
qualitative and quantitative differences were detected in the analysis of the peptidomas 
from healthy and pathological samples. In fact, as reported in the Table 1 , averaged area of 
each peak of all detected peptides resulted to be different, showing that some of them were 
differently represented in each sample. The above mentioned peptides from complement C3 
and inter-alpha trypsin inhibitor were poorly represented in the healthy serum samples, 
whereas fibrinogen alpha chain peptides were strongly represented in these sera, as well as 
coagulation factor XIII A peptides. 
 
 
Fig. 1. Positive ion mode MALDI-TOF/TOF fragmentation spectrum of m/z 1536.44 
corresponding to peptide 20-35 from fibrinogen alpha chain protein from healthy serum.  
3.2 The proteins profile from 2D-electrophoresis is different 
After depletion of the most abundant proteins, a two dimensional electrophoretic separation 
of the two sera samples was performed, thus leading to the construction of 2D protein maps 
of healthy and myocarditis samples.  Each gel was blue comassie stained.  Image analysis 
was performed on the two sets of 2D maps (from healthy control and pathologic sera) 
clearly showing that the protein profile is quite different, as reported in figure 2. The protein 
spots which resulted to be differentially expressed in the two samples were then submitted 
to mass spectral identification. Fig 2 shows all the spots we chose.  
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        (a)        (b) 
Fig. 2. Two-dimensional electrophoresis gels of healthy (A) and myocarditis affected (B) sera 
proteins. Arrows and numbers in (B) correspond to numbers of identified spots in Table 2. 
It should be underlined that all the spots we further analysed were taken from the 
pathologic serum and results are summarized in Table 2. 
 
Spot Accession number Protein
1 P02790 Hemopexin
2 P02790 Hemopexin
3 P02790 Hemopexin
4 P02790 Hemopexin
5 P02790 Hemopexin
6 P02787 Serotransferrin
7 P01008 Antithrombin III
8 P01008 Antithrombin III
9 P01011 Alpha-1 antichymotrypsin 
10 P01024 Complement C3
11 P04196 Histidine rich glycoprotein 
12 P01024 Complement C3
13 P00738 Haptoglobin
14 P04196 Histidine rich glycoprotein 
15 Q14624 Inter-alpha-trypsin inhibitor heavy chain H4 
16 P08603 Complement factor H
17 P08603 Complement factor H
18 P03952 Plasma kallikrein
19 P06727 Apolipoprotein A-IV
20 P00738 Haptoglobin
21 P00738 Haptoglobin
22 P36955 Pigment epithelium-derived factor 
23 P36955 Pigment epithelium-derived factor 
24 P36955 Pigment epithelium-derived factor 
Table 2. List of proteins identified by LC-MS/MS of spots excised from two-dimensional 
gels of sera taken from myocarditis affected patients. 
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Proteins excised from the gel were reduced alkylated and, in situ, digested with trypsin. The 
resulting peptide mixtures were directly analysed by LC-MS/MS according to the peptide 
mass fingerprinting procedure. MS and MS-MS obtained data were used to search for a non-
redundant sequence using the in-house MASCOT software, taking advantage of the 
specificity of trypsin and of the taxonomic category of the samples. The number of 
measured masses that matched within the given mass accuracy of 20 ppm was recorded and 
the proteins that had the highest number of peptide matches were examined.  
Thanks to this approach, we could identify many proteins differently expressed in the two 
sera. Among identified proteins, hemopexin (Dooley H et al., 2010) , complement C3 
(Adamsson Eryd S et al., 2011, Onat A et al., 2011), plasma kallikrein (Kolte D et al.,2011) are 
undoubtedly related to inflammatory events and most interestingly they resulted clearly 
over expressed in the pathologic sample.  
A preliminary speculation on identified proteins might involve the function of hempopexin. 
As shown by literature data (Dooley H et al., 2010, : Mauk MR et al., 2011, Larsen R et 
al.,2010), hemopexin is a serum protein with the very well known function of scavenging the 
heme released or lost by the turnover of heme proteins such as haemoglobin or by 
haemolysis caused by parasitic infection, and thus protects the body from the oxidative 
damage that free heme can cause (Larsen R et al.,2010).  Myocarditis itself it’s not related to 
haemolysis phenomena, but some viral infections may cause it, therefore, finding a very 
high level of hempoxin in a myocarditis affected patient might be a putative marker of the 
inflammation itself (quite common are in fact viral myocarditis). 
Moreover we found some connections between differently expressed proteins in pathologic 
serum and identified free peptides; in particular we could detect some free peptides some 
peptides from proteins Complement C3, Inter-alpha-trypsin inhibitor heavy chain H4, 
Antithrombin III which results over expressed in pathologic serum, (see Tab 1). 
3.3 Boronate affinity chromatography 
The third part of this work focus on the investigation of one of the most important post-
translational modification, the glycosylation. The importance of investigation of post-
translational modifications (PTM) is notably increased in the proteomic era, as they play a 
critical role in cellular functioning and they vary in response to environmental stimuli, 
signalling modulators or development of diseases (Laurell E et al., 2011). PTMs can affect 
biological functions thus playing a critical role in cellular functioning. Moreover, they can 
vary in response to environmental stimuli, thus finely tuning cellular mechanisms and their 
deregulation might be involved in the development of diseases. A huge number of different 
types of PTMs have been identified but only a few are reversible and important for 
regulation of biological processes (Wu C et al. 2011). The pattern of PTMs on proteins 
constitute a molecular code that dictates protein conformation, cellular location, 
macromolecular interactions and activities, depending on cell type, tissue and 
environmental conditions. Understanding this code is the major challenge of proteomics in 
post-genomic era. Existing methodologies for PTMs identification essentially rely on specific 
enrichment procedures able to selectively increase the amount of modified peptides. These 
procedures have to be integrated with sophisticated mass spectrometric experiments to 
address the identifications of PTMs. The development of a variety of new technologies for 
exploring the structures of the sugar chains has opened up a new frontier in the glycomics 
field. Moreover recent progress in mass spectrometry led to new challenges in glycomics, 
including the development of rapid glycan enrichment. Recently our group introduced an 
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easy to handle strategy to give preliminary insights for the comparison of glycoproteomes in 
healthy and pathological human sera, by using a single Con A affinity chromatography step 
coupled with mass spectrometry techniques. The strategy led both to the identification of 69 
different glycosylation sites within 49 different proteins and to the definition of the 
glycosylation patterns. Moreover, glycoform distribution in myocarditis and hepatic 
carcinoma has been reported. The analysis of glycan profiling, once extracted from serum 
glycopeptides, is essential for comparative studies on different sera samples thus providing 
a useful tool for the development of screening procedures (Carpentieri A, Giangrande C, et 
al., 2010). 
In this paper, a different simple and rapid procedure to obtain an overview of the 
glycosylation sites profiling in the two samples was accomplished. This was achieved by 
enriching for the N-linked glycopeptides resulting from trypsin digestion of sera samples in 
order to enhance the identification of N-glycosylation sites using LC-MS/MS. The analyses 
have been carried out by using healthy sera as control.  
To reduce the complexity of the whole sample, Boronate affinity purification was rapidly 
performed in batch after tryptic digestion. Thanks to the vicinal diols binding capacity no 
discrimination on the basis of the glycan type was performed thus, in a proof of principle, 
all glycopeptides could be selected. The recovered glycopeptides were then deglycosylated 
by PNGase F treatment and the peptide mixtures directly analysed by LC-MS/MS. 
The analyses were performed on intact serum samples without any pre-purification step or 
removal of most abundant proteins. The peptide component of the eluted fraction was 
analysed by tandem mass spectrometry. Similar analyses were carried out on the unbound 
Boronate fractions, mainly containing non-glycosylated peptides.  
The data were then pooled and summarised in Table 3. The results presented here 
demonstrated that Boronate affinity chromatography on serum tryptic digests is a useful 
tool to enhance the detection by LC-MS/MS of glycopeptide. Another advantage of the 
strategy relies on the fact that it was performed on glycopeptides instead of glycoproteins, 
therefore there were no SDS-PAGE step, no isolation of the individual glycoproteins and no 
in situ digestion. This allowed the detection of less abundant glycopeptides together with 
the most represented ones, such as those deriving from albumins or immunoglobulins. 
As shown in Table 3, all the selected peptides still contained the conserved N-glycosylation 
motif (Asn-X-Ser/Thr), thus indicating that N-glycosylation peptides were isolated with 
high selectivity. This analysis led both to the localization of the modification sites and 
identification of glycoproteins. 
The presence of a putative N-glycosylation site was confirmed by the fact that peptides mass 
was increase of 1 Da, due to the conversion of Asn into Asp after PNGase F incubation. 
However, some non-specific peptides, namely non-glycosylated peptides, were detected in 
the eluted Boronate fraction, and identified as belonging to most abundant proteins like 
albumin. 
Spontaneous deamidation seems rather unlikely for generating the results presented, 
although it cannot be excluded completely. Most MS/MS spectra giving positive hits were 
derived from doubly charged precursor ions that resulted predominantly in y-ion series.  
As a whole, using Boronate affinity approach we could confirm the previously identified 
glycosylation sites based on ConcanavalinA enrichment and 5 more glycosylation sites were 
identified thus refining previous data (Carpentieri A, Giangrande C, et al., 2010) on 
myocarditis glycoproteome.  
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 Protein Sequence Peptide 
P01011 
Alpha-1-
antichymotrypsin 
YTGN*ASALFILPDQDKH,M 268-283 
P02763 
Alpha-1-acid 
glycoprotein 
SVQEIQATFFYFTPN*KTEDTIFLRH,M 
QDQCIYN*TTYLNVQRH,M 
58-81 
87-101 
P01009 Alpha-1-antitrypsin 
YLGN*ATAIFFLPDEGKH,M 
QLAHQSN*STNIFFSPVSIATAFAMLSL
GTKH 
ADTHDEILEGLNFN*LTEIPEAQIHEGF
QELLRH,M 
268-283 
64-93 
94-125 
P01023 
Alpha-2-
macroglobulin 
SLGNVN*FTVSAEALESQELCGTEVPS
VPEHGRKH 
864-886 
P43652 Afamin 
DIENFN*STQKH,M 
YAEDKFN*ETTEKH 
28-37 
396-407 
P01008 Antithrombin III 
LGACN*DTLQQLMEVFKH,M 
SLTFN*ETYQDISELVYGAKH,M 
124-139 
183-201 
P04114 Apolipoprotein B-100 
FN*SSYLQGTNQITGRH,M 
FVEGSHN*STVSLTTKH 
AEEEMLEN*VSLVCPKM 
YDFN*SSMLYSTAKM 
1522-1536 
3405-3419 
27-41 
3462-3474 
P05090 Apolipoprotein D ADGTVNQIEGEATPVN*LTEPAKM 83-104 
P02749 Apolipoprotein H 
VYKPSAGN*NSLYRH 
LGN*WSAMPSCKM 
155-167 
251-261 
O75882 Attractin 
IDSTGN*VTNELRH,M 
GPVKMPSQAPTGNFYPQPLLN*SSMC
LEDSRH 
411-422 
1023-1052 
P00450 Ceruloplasmin 
EHEGAIYPDN*TTDFQRH,M 
EN*LTAPGSDSAVFFEQGTTRH,M 
129-144 
396-414 
P08603 
Complement 
factor H 
ISEEN*ETTCYMGKH 
MDGASN*VTCINSRH,M 
IPCSQPPQIEHGTIN*SSRM 
SPDVIN*GSPISQKH 
907-919 
1024-1036 
868-885 
212-224 
P10909 Clusterin LAN*LTQGEDQYYLRH,M 372-385 
Q8IWV2 Contactin-4 LN*GTDVDTGMDFRM 64-76 
P05156 Complement factor 1 FLNN*GTCTAEGKH,M 100-111 
P01024 Complement C3 TVLTPATNHMGN*VTFTIPANRH 74-94 
P0C0L4 Complement C4-A GLN*VTLSSTGRH,M 1326-1336 
P02748 
Complement 
component C9 
AVN*ITSENLIDDVVSLIRH,M 413-430 
Q14517 Protocadherin-fat 1 
QVYN*LTVRAKDKM 
FSMDYKTGALTVQN*TTQLRSRM 
994-1005 
1930-1950 
P02765 
Alpha-2-HS-
glycoprotein 
VCQDCPLLAPLN*DTRH,M 
AALAAFNAQNN*GSNFQLEEISRH 
145-159 
166-187 
Q03591 
Complement factor H 
related protein 1 
LQNNENN*ISCVERH 120-132 
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 Protein Sequence Peptide 
Q13439 
Golgin subfamily A 
member 4 
HN*STLKQLMREFNTQLAQKH 1990-2008 
P02790 Hemopexin 
SWPAVGN*CSSALRH,M 
ALPQPQN*VTSLLGCTHH,M 
181-193 
447-462 
P00738 Haptoglobin 
VVLHPN*YSQVDIGLIKH,M 
MVSHHN*LTTGATLINEQWLLTTAKH
,M 
NLFLN*HSEN*ATAKH,M 
236-251 
179-202 
203-215 
P04196 
Histidine rich 
glycoprotein 
VEN*TTVYYLVLDVQESDCSVLSRH 
VIDFN*CTTSSVSSALANTKH,M 
61-83 
121-139 
P05155 
Plasma protease C1 
inhibitor 
VGQLQLSHN*LSLVILVPQNLKH,M 344-364 
P01857 
Ig alpha-1 chain C 
region 
LSLHRPALEDLLLGSEAN*LTCTLTGL
RH 
127-153 
P01859 
Ig gamma-2 chain C 
region 
TKPREEQFN*STFRH 
TPLTAN*ITKH 
168-180 
200-208 
P01860 
Ig gamma-1 chain C 
region 
EEQYN*STYRH,M 136-144 
P01591 
Immunoglobulin J 
chain 
EN*ISDPTSPLRH,M 48-58 
P40189 
Interleukin-6 receptor 
beta 
QQYFKQN*CSQHESSPDISHFERM 812-833 
P56199 Integrin alpha-1 SYFSSLN*LTIRM 1096-1106 
P29622 Kallistatin DFYVDEN*TTVRH 232-242 
P01042 Kininogen-1 LNAENN*ATFYFKH,M 389-400 
P11279 
Lysosome-associated 
membrane 
glycoprotein 1 
DPAFKAAN*GSLRM 314-325 
P01871 Ig mu chain C region 
YKN*NSDISSTRH 
GLTFQQN*ASSMCVPDQDTAIRM 
44-54 
204-223 
Q9HC10 Otoferlin NEMLEIQVFN*YSKVFSNKH,M 59-76 
Q5VU65 
Nuclear pore 
membrane 
glycoprotein 210-like 
EVVVN*ASSRH 1551-1559 
Q9Y5E7 Protocadherin beta 2 ETRSEYN*ITITVTDFGTPRM 414-432 
P36955 
Pigment epithelium 
derived factor 
VTQN*LTLIEESLTSEFIHDIDRH 282-303 
P27169 
Serum 
paraoxanase/arylester
ase1 
HAN*WTLTPLKH 250-259 
P49908 Selenoprotein P EGYSN*ISYIVVNHQGISSRH 79-97 
Q9Y275 
Tumor necrosis factor 
ligand superfamily 
member 13B 
CIQNMPETLPN*NSCYSAGIAKM 232-252 
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 Protein Sequence Peptide 
P40225 Thrombopoietin IHELLN*GTRGLFPGPSRRM 250-267 
P02787 Serotransferrin 
QQQHLFGSN*VTDCSGNFCLFRH,M 
CGLVPVLAENYN*KSDNCEDTPEAGY
FAVAVVKM 
622-642 
421-452 
P07996 Thrombospondin 1 VVN*STTGPGEHLRH,M 1065-1077 
P04004 Vitronectin NN*ATVHEQVGGPSLTSDLQAQSKM 85-107 
P25311 
Zinc-alpha-2-
glycoprotein 
DIVEYYN*DSN*GSHVLQGRH,M 100-117 
P02766 Transthyretin ALGISPFHEHAEVVFTAN*DSGPRH 101-123 
Table 3. LC/MSMS analysis for the identification of glycosylation sites, H indicates peptides 
deriving from healthy serum and M indicates the ones from myocarditis serum. 
4. Conclusions 
In biomedical applications, a comparative approach is usually employed to identify proteins 
that are up and down regulated in a disease specific manner for use as diagnostic markers 
or therapeutic targets. This report represents an overview of the investigation at molecular 
level of myocarditis by using a proteomic approach .  
Serum proteins (including the N-glycosylation sites profiling) and glycoproteins and free 
peptides occurring in human sera from healthy donors were compared to the ones from 
myocarditis patients. This procedure, allowed the identification of several N-glycosylation 
sites by a single-step proteomic approach, contemporarily probing an entire complex 
sample by LC-MS/MS. Thanks to the depletion of the serum most abundant proteins, we 
could detect some of the very weakly represented free peptides, whose presence is 
connected to the pathology itself.   The high resolution, the sensitivity and the 
reproducibility of the used techniques led to the identification of some up regulated proteins 
in the serum from a myocarditis affected patient, all these proteins are connected to 
inflammatory events and one in particular (hemopexin) opens the way to new speculations 
in serum proteins as a specific marker for pathologic state. 
 Finally, this proteomic approach represents a new opportunity for therapeutics and early 
diagnostics, for the screening of proteic biomarkers in pathological status. Finding a 
biomarker molecule that precisely indicates certain kind of pathology, is something quite 
difficult to achieve since it requires a huge background in many different fields of clinical 
investigation.  Here we contribute with putative diagnostic species that could really be 
helpful for an early diagnosis myocarditis event. 
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